drugset / Trial / NCT06180889

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

NCT06180889

Phase 2 Active not recruiting 241 enrolled Suzhou Alphamab Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Timeline

Start
2023-12-20
Primary completion
2025-12-15
Completion
2026-04-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject KN060 Unknown Intravenous

Indications